Critical Reviews™ in Oncogenesis

ISSN for PRINT: 0893-9675

For Online Access

Best Paper Award Selection - Editorial Board Site

2007, Volume13

Petra I. Lorenzo
Department of Molecular Biosciences, University of Oslo, Postboks 1041, Blindern, 0316 Oslo, Norway

Yke J. Arnoldussen
Department of Molecular Biosciences, University of Oslo, Postboks 1041, Blindern, 0316 Oslo, Norway

Fahri Saatcioglu
Department of Molecular Biosciences, University of Oslo, Postboks 1041, Blindern, 0316 Oslo, Norway

Prostate cancer is the most frequently diagnosed noncutaneous cancer in men in Western countries. As in the normal prostate, the initial stages of prostate cancer progression depend on androgens that increase proliferation and inhibit apoptosis. Androgen-deprivation therapy is the major course of treatment in recurrent and metastatic prostate cancer. However, in most cases prostate cancer progresses to an apoptosis-resistant androgen-independent stage for which there is no available therapy. It is therefore important to understand the molecular mechanisms underlying prostate cancer progression, and how prostate cancer cells evade apoptotic mechanisms that give rise to their uncontrolled growth behavior. Here, we have reviewed the most important signaling pathways implicated in prostate cancer apoptosis and cell growth and how they may be deregulated during prostate cancer progression.

Download article, 1-38 pages

Article price - $35.00

  Next article >>